ANAPTYSBIO, INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$108M
↑+151.1% +$65Mvs FY2024 (Q4)
Gross Profit
$108M
↑+151.1% +$65Mvs FY2024 (Q4)
Operating Income
$13M
↓-69.3% -$30Mvs FY2024 (Q4)
Net Income
$13M
↓-69.5% -$30Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $108M | $43M |
| COGS | $0 | $0 |
| Gross Profit | $108M | $43M |
| R&D | $0 | $0 |
| SG&A | $0 | $0 |
| D&A | $131K | $145K |
| Other OpEx | $95M | $19K |
| Operating Income | $13M | $43M |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $13M | $43M |
| Tax | $81K | $0 |
| Net Income | $13M | $43M |
QuarterCharts · SEC EDGAR data · ANAB · Comparing FY2025 (Q4) vs FY2024 (Q4)